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Background 
Sexually transmitted diseases (STDs) are major causes of acute illness and infertility worldwide. The World 
Health Organization (WHO) estimates 499 million new cases of curable STDs occur annually worldwide in adults 
aged 15-49 years. The largest number of new infections occurs in Southeast Asia, followed by sub-Saharan 
Africa, Latin America, and the Caribbean. In low-income countries, STDs rank in the top 5 disease categories for 
which adults seek healthcare. 
 
The prevalence of STDs in refugee populations is not well characterized and likely varies among populations. It is 
important to consider STDs in refugees in order to minimize or prevent acute and chronic sequelae, as well as 
prevent transmission to others. 
These domestic STD screening guidelines are intended for state public health departments and medical 
providers in the United States who conduct the initial medical screening for newly arrived refugees. These 
guidelines are based on current medical knowledge and the advice of experts in refugee health, and are meant 
to provide healthcare providers with best practices for diagnosing sexually transmitted diseases in refugees. 
Medical Screening 
Overseas Pre-Departure Screening and Testing 
For all refugees ≥15 years of age, clinical evaluation and treatment for identified infection are mandatory for the 
following STDs: 
 Syphilis (laboratory testing required) 
 Gonorrhea 
 Note:  Chlamydia trachomatis testing is not required (not considered a disease of public health 
significance under 42 Code of Federal Regulations part 34); however, many panel physicians use test kits 
that screen for both chlamydia and gonorrhea. When these tests are used, panel physicians are directed 
by CDC to document the test results in the remarks section of the DS 3026 (Medical History and Physical 
Examination Worksheet). If a refugee applicant for U.S. admission tests positive, the treatment provided 
should also be listed on the remarks section of the DS 3026 and the applicant should be given a “Class B 
Other” classification for chlamydia infection.  
The medical history and physical examination should include a search for symptoms or lesions consistent with 
these diseases; however, many sexually transmitted infections can be asymptomatic. Routine laboratory testing 
for syphilis is performed for all applicants ≥15 years of age. Applicants younger than 15 years of age must be 
tested if there is reason to suspect infection or if there is a history of syphilis. Syphilis serologic testing is done 
according to the CDC Technical Instructions for Syphilis for Panel Physicians. Further testing is performed, as 
necessary, to confirm a suspected syphilis diagnosis.  
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All applicants ≥15 years of age must also be tested for gonorrhea. Applicants <15 years of age must be tested if 
there is a history of gonorrhea or reason to suspect infection. Testing should be done according to the CDC 
Technical Instructions for Gonorrhea for Panel Physicians, effective as of October 1, 2016.  
In January 2010, HIV was removed from the list of excludable infections, and is no longer routinely tested for 
overseas. Refugees who are diagnosed with syphilis or gonorrhea prior to departure are offered HIV testing. As 
of March 28, 2016, chancroid, lymphogranuloma venerum, and granuloma inguinale were also removed from 
the list of communicable diseases of public health significance. Therefore, evaluation for these three diseases is 
no longer required as part of the U.S. immigration medical screening process. For additional information, please 
see Part 34 Final Rule, issued on January 26, 2016. 
Recommendations for Post-Arrival Screening and Evaluation 





 Granuloma inguinale/donovanosis 
 Lymphogranuloma venereum 
 Genital herpes 
 Genital warts 
 Trichomoniasis 
 HIV 
A complete evaluation for all STDs includes a thorough medical history, physical examination, and, for specific 
infections, testing, as many infections are asymptomatic. 
The optimal medical history includes asking about sexual history, including any contact with a person who has, 
or had, a known STD, and asking about any history of signs or symptoms suggestive of an STD. Common signs 
and symptoms of infection include urethral, vaginal, or rectal discharge; dysuria; rash; sores on the genitals, 
anus, or mouth; or a rash on the palms or soles of the feet. 
Pertinent elements of the physical examination for STDs include palpation for enlarged or tender lymph nodes, 
inspection of skin and oral mucosa, and an external anal and genital examination, including inspection for 
discharge, ulcers, or rashes. In refugees who previously experienced trauma (e.g., sexual assault victims), the 
anal and genital examination may be postponed until the refugee establishes a trusting relationship with a 
provider. 
The following summarizes the currently recommended testing: 
 Screening syphilis testing should be performed routinely for refugees in the following categories: 
o All refugees >15 years of age, if no overseas results are available 
o Children <15 years of age who are at risk for congenital syphilis (e.g., mother who tests positive 
for syphilis), who are sexually active, or have been sexually assaulted should be evaluated 
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according to the Congenital Syphilis section of the CDC Sexually Transmitted Diseases Treatment 
Guidelines, 2015. 
Nontreponemal testing (e.g., Venereal Disease Research Laboratory [VDRL] and Rapid Plasma Reagin 
[RPR]):  Refugees with a positive nontreponemal screening test (e.g., VDRL or RPR) should have 
confirmatory treponemal testing (e.g., fluorescent treponemal antibody absorbed [FTA-ABS], 
Treponema pallidum passive particle agglutination assay [TP-PA], various enzyme-linked 
immunosorbent assays [EIAs or ELISAs], chemiluminescence immunoassays).  The use of a “reverse 
screening” algorithm (e.g., initial screening with a treponemal test, followed by nontreponemal 
testing) is another option for serologic testing when it is being used as a local standard of care. 
Further evaluation, including evaluation for neurosyphilis, and treatment should be instituted in 
persons with a positive screening test, according to the CDC Sexually Transmitted Diseases 
Treatment Guidelines, 2015. 
 Chlamydia: Nucleic acid amplification tests 
o Female refugees <25 years old who are sexually active or female refugees >25 years who have 
risk factors (e.g., new sex partner or multiple sex partners, sex partner with concurrent partners, 
sex partner who has a sexually transmitted infection) who do not have documented pre-
departure testing 
o Female refugees with abnormal vaginal or rectal discharge, intermenstrual vaginal bleeding, or 
lower abdominal or pelvic pain 
o Male refugees with urethral discharge, dysuria, or rectal pain or discharge 
 Gonorrhea: Nucleic acid amplification tests 
o Female refugees <25 years old who are sexually active or females >25 years who have risk 
factors (e.g., new sex partner or multiple sex partners, sex partner with concurrent partners, sex 
partner who has a sexually transmitted infection) who do not have documented pre-departure 
testing 
o Female refugees with abnormal vaginal or rectal discharge, intermenstrual vaginal bleeding, or 
lower abdominal or pelvic pain 
o Male refugees with urethral discharge, dysuria, or rectal pain or discharge. 
 
NOTE: Consider testing any refugee who has a history of sexual assault for these STDs; management and 
evaluation of sexually assaulted children requires consultation with an expert (CDC Sexually Transmitted 
Diseases Treatment Guidelines). 
HIV testing is also strongly encouraged in newly arriving refugee populations according to current CDC guidelines 
for Screening for HIV Infection During the Refugee Domestic Medical Examination. Testing for HIV is particularly 
important and encouraged for any refugee with another confirmed STD. 
The most current information on STDs, including treatment and laboratory guidelines, is available at: 
 CDC STD website (http://www.cdc.gov/STD/) 
 CDC STD Treatment website (http://www.cdc.gov/std/tg2015/default.htm) 
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 CDC Sexually Transmitted Diseases Treatment Guidelines, MMWR 2015  
(http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm)  
 U.S. Preventive Services Task Force Recommendations for STI Screening 
(http://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-recommendations-for-sti-screening)  




 Screening for Syphilis Infection in Nonpregnant Adults and Adolescents: U.S. Preventive Services Task 
Force Recommendation Statement 
(https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/syp
hilis-infection-in-nonpregnant-adults-and-adolescents)  
Clinical Presentations and Diagnostic Testing for Specific STDs 
Clinical presentation, screening, and diagnostic aspects of STDs that may be encountered in refugees are 
discussed in this document. These STD screening guidelines are intended for state public health departments 
and medical providers in the United States. These guidelines are based on current medical knowledge and the 
advice of experts in refugee health, and are meant to provide healthcare providers with currently accepted best 





Syphilis, which is caused by the bacterium Treponema pallidum, has often been called the “great imitator” 
because many of its signs and symptoms are indistinguishable from those of other diseases. Many refugees who 
are infected do not recall ever having had symptoms. Asymptomatic latent infection is detected through 
serologic screening. 
Typical signs and symptoms of syphilis, listed by stage, include the following: 
 Primary stage (generally occurs 10-90 days after exposure): 
Ulcer or chancre at the inoculation site (usually the genitals, rectum, tongue, or lips) 
 Secondary stage (generally occurs 2-10 weeks after the chancre appears): 
Skin rash marked by red or reddish-brown macules on the palms and soles or other parts of the body; 
mucocutaneous lesions; lymphadenopathy; anorexia; fever; headaches; weight loss; fatigue 
 Latent stage (early latent and late latent, begin when primary or secondary symptoms disappear and 
may last for years): 
No signs or symptoms present 
 Tertiary stage (generally occurs 10-20 years after infection): 
Cardiac manifestations (e.g., aortitis), ocular manifestations (e.g., optic atrophy, uveitis, pupillary 
disorder), auditory abnormalities (e.g., asymmetric deafness, tinnitus), neurologic manifestations (e.g., 




Signs and symptoms of neurosyphilis include motor or sensory deficits, cranial nerve dysfunction, meningitis, 
stroke, acute or chronic altered mental status, loss of vibration sense, and auditory or ophthalmic abnormalities. 
Neurosyphilis may occur at any stage of disease. 
Congenital syphilis: 
Congenital syphilis may present as nonimmune hydrops, jaundice, hepatosplenomegaly, rhinitis, skin rash, or 
pseudoparalysis of an extremity. In older children, signs of untreated congenital infection include interstitial 
keratitis (5-20 years of age), cranial nerve deafness (10-40 years of age), Hutchinson teeth (peg-shaped, notched 
central incisors), anterior bowing of the shins, frontal bossing, mulberry molars, saddle nose, rhagades (linear 
scars around the mouth), and Clutton’s joints (symmetric, painless swelling of the knees). Prevention and 
detection of congenital syphilis depends on identification of syphilis in pregnant women by serology. For specific 
more information on congenital syphilis see CDC congenital syphilis. 
Syphilis Serology: 
Serologic tests for syphilis require the use of two tests: nontreponemal tests that use a nonspecific cardiolipin 
antigen and confirmatory tests that use specific T. pallidum antigens (Table 1).  A nontreponemal test, such as 
VDRL or RPR, may be used for screening. Positive results on these nontreponemal tests should be confirmed 
using a treponemal test (e.g., FTA-ABS, TP-PA, EIAs, chemiluminescence immunoassays). The use of only one 
type of test is insufficient for diagnosis, since all tests have limitations, including the possibility of false-positive 
test results. False-positive nontreponemal test results can be associated with various medical conditions 
unrelated to syphilis, including autoimmune disorders, older age, and injection drug use. 
Screening tests, such as the VDRL and RPR, are relatively simple to perform and provide rapid results. Both VDRL 
and RPR quantitative titer usually correlate with disease activity, and are used to monitor the effect of 
treatment. If treatment is successful, the antibody titer gradually declines. A four-fold change in titer (e.g., from 
1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. 
Sequential nontreponemal tests should be performed by using the same testing method, because quantitative 
results from the two tests cannot be compared directly; RPR titers are often slightly higher than VDRL titers. The 
timing of follow-up testing is dictated by the clinical presentation and stage of infection, as well as the HIV status 
of the refugee, and is detailed in the current treatment guidelines (1). 
Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful 
treatment of syphilis. Screening with treponemal tests is not recommended in high-prevalence settings, because 
these tests will be reactive in people with previous successful treatment, as well as those with untreated or 
incompletely treated infection. 
Recently, some clinical laboratories have begun using a “reverse screening” algorithm.  The use of this algorithm 
is acceptable when it is considered the local standard of care.  This method can identify persons previously 
treated for syphilis, those with untreated or incompletely treated syphilis, and persons with false-positive 
results. Persons with a positive treponemal screening test should have a standard nontreponemal test, with titer 
performed reflexively by the laboratory to guide patient management decisions. If the nontreponemal test is 
negative, the laboratory should perform a different treponemal test (preferably one based on different antigens 
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than the original test) to confirm the results of the initial test. If a second treponemal test is negative and the 
epidemiologic risk and clinical probability for syphilis are low, the initial treponemal test is considered a false 
positive and further evaluation or treatment is not indicated. People with a history of previous treatment 
require no further management unless sexual history suggests likelihood of re-exposure. In this instance, a 
repeat nontreponemal test in 2–4 weeks is recommended to evaluate for early infection. Those without a 
history of treatment for syphilis should be offered treatment. Unless history or results of a physical examination 
suggest a recent infection, previously untreated persons should be treated for late latent syphilis. For more 
information, refer to CDC Sexually Transmitted Diseases Treatment Guidelines. 
Cerebrospinal Fluid Examination: 
Involvement of the central nervous system can occur during any stage of syphilis; therefore, any person who has 
syphilis and signs or symptoms of neurologic or ophthalmic involvement should have a cerebrospinal fluid (CSF) 
evaluation. The diagnosis of neurosyphilis depends on a combination of CSF tests (elevated cell count or protein 
and a reactive CSF-VDRL), with reactive serologic tests and neurologic signs or symptoms. The treatment 
guidelines provide in-depth information on diagnosis and treatment, and expert consultation may be needed 
when deciding how to evaluate an individual or interpret testing (1). 
Other Diagnostic Tests: 
Because early treatment decreases the possibility of transmission, presumptive treatment of suspected 
infectious syphilis is recommended on the basis of clinical presentation and epidemiologic circumstances (high 
incidence of disease among populations or communities and travel history). 
Syphilis in children (either congenital or acquired) must be properly evaluated. The diagnosis of congenital 
syphilis is complicated by transplacental transfer of maternal nontreponemal and treponemal IgG antibodies to 
the fetus, making it difficult to interpret reactive serologic tests for syphilis in newborns born to mothers 
seropositive for syphilis.  Further information on evaluation for congenital syphilis is available in published 
guidelines, including a section in CDC’s STD Treatment Guidelines (2015) and the American Academy of 
Pediatrics Red Book. Infants >1 month of age and children who have a reactive serology should be examined, 
and have maternal serology and records reviewed to assess whether they have congenital or acquired syphilis. 
Other Treponema pallidum infections 
Infection with other T. pallidum subspecies (i.e., T. pallidum subsp. pertenue, T. pallidum subsp. endemicum, and 
T. carateum) is acquired through contact with infected skin. These may result in a simple rash, but may progress 
and cause disfiguring skin lesions. Unlike syphilis, these infections are not considered sexually transmitted. Long-
term infection can lead to deformation of bone and nasopharyngeal tissue. Infection with any of these 
subspecies can also cause seroreactivity for treponemal and nontreponemal tests used for diagnosis of syphilis; 
therefore, it is important to obtain a history of sexual and nonsexual exposures and consider T. pallidum 






Chlamydia, caused by the bacterium Chlamydia trachomatis, is the most frequently reported STD in the United 
States. The highest prevalence of infection is observed in persons 15-25 years of age. Asymptomatic infection is 
common. Screening of sexually active refugee women <25 years old, or of women >25 years old with risk factors 
(e.g., new sex partner or multiple sex partners, sex partner with concurrent partners, sex partner who has a 
sexually transmitted infection), is recommended in the United States. In women, untreated infection can cause 
pelvic inflammatory disease, ectopic pregnancy, and infertility. Rarely, genital chlamydia infection can cause 
arthritis that may be accompanied by skin lesions and inflammation of the eye and urethra (reactive arthritis or 
Reiter’s syndrome) (2). There are few published data regarding prevalence rates of chlamydia in refugee 
populations arriving in the United States, although one study of more than 2,500 refugees found a rate of 0.6%, 
which is substantially lower than U.S. prevalence rates (3). 
Asymptomatic infection is common; however, women may report abnormal vaginal discharge or a burning 
sensation when urinating. Other symptoms include abdominal pain, lower back pain, nausea, fever, pain during 
intercourse (dyspareunia), or bleeding between menstrual periods. Men with signs or symptoms may have 
penile discharge; an itching or burning sensation when urinating; rectal pain, discharge, or bleeding; or 
epididymitis. Autoinoculation may occur in men or women, and can be associated with conjunctivitis. 
Chlamydia trachomatis infection in infants occurs perinatally and most frequently presents as conjunctivitis that 
develops 5-12 days after birth. It can also cause an afebrile pneumonia, with onset 1-3 months after birth. Signs 
of C. trachomatis pneumonia include a repetitive staccato cough with tachypnea and hyperinflation and bilateral 
diffuse infiltrates on chest radiograph. 
Diagnostic Testing: 
Diagnosis of C. trachomatis urogenital infection in women can be made by testing first catch urine or cervical or 
vaginal swab specimens. Urethral C. trachomatis infection in men can be diagnosed by testing first catch urine 
specimens. 
Nucleic acid amplification tests are the most sensitive tests available for detection of C. trachomatis. Further 
information on diagnostic testing can be obtained from existing guidelines. 
Gonorrhea 
Clinical Presentation: 
Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is the second most common bacterial STD in the 
United States. The majority of gonococcal urethral infections in men produce symptoms. However, among 
women, more than 30% of infections are asymptomatic; untreated infection can result in complications such as 
pelvic inflammatory disease (PID), infertility, and ectopic pregnancy. Similar to chlamydia, there are little 
published data regarding prevalence rates of gonococcal infection in refugee populations arriving in the United 
States. The single publication on reporting rates of STDs in newly arriving refugees found that out of more than 
2,500 refugees, only 0.2% were infected (3). 
Signs and symptoms of gonorrhea may appear 1-14 days after a person is exposed to an infected person. 
In men, signs and symptoms may include: 
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 Pain or burning sensation when urinating 
 Penile discharge 
 Epididymitis 
 Rectal discharge, anal itching, soreness, bleeding, or painful bowel movements 
In women, signs and symptoms may include: 
 Pain or burning sensation when urinating 
 Vaginal discharge 
 Intermenstrual bleeding 
 Rectal discharge, anal itching, soreness, bleeding, or painful bowel movements 
 Lower abdominal pain and dyspareunia 
Other sites of infection include the eyes (gonococcal conjunctivitis) and pharynx. Disseminated gonococcal 
infection is associated with arthritis, tenosynovitis, skin lesions, fever or a combination of these findings. Skin 
changes range from maculopapular or pustular to hemorrhagic rashes and lesions. Arthritis and tenosynovitis 
most typically affect the wrists, knees, and ankles. 
Gonococcal infection among infants usually results from exposure to infected cervical exudate at birth. Typically, 
an acute illness develops 2-5 days after birth, and may present as ophthalmia neonatorum, which may be 
complicated by a perforation of the globe of the eye and result in blindness. Other manifestations in infants are 
scalp abscesses, rhinitis, vaginitis, urethritis, arthritis, meningitis, and sepsis. 
Diagnostic Testing: 
Specific diagnostic testing for gonorrhea may be performed on endocervical, vaginal, male urethral, or urine 
specimens. For screening purposes, urine samples tested by nucleic acid amplification tests are highly sensitive 
and specific. A Gram stain of discharge, or a urethral swab showing intracellular gram-negative diplococci, 
supports the diagnosis and may be sufficient to confirm gonorrhea in symptomatic men. 
Because nonculture-based tests do not permit antimicrobial susceptibility testing, in cases of persistent 
gonococcal infection following treatment, both bacterial culture and antimicrobial susceptibility testing should 
be assessed. Refugees infected with N. gonorrhoeae are frequently co-infected with Chlamydia trachomatis. 
Chancroid 
Clinical Presentation: 
Chancroid is caused by the bacterium Haemophilus ducreyi and results in painful, superficial ulcers, often with 
regional lymphadenopathy. Chancroid occurs in Asia, Africa, and the Caribbean, and is an important cofactor of 
HIV transmission. The genital ulcer from chancroid is painful, tender, and nonindurated. Symptoms usually occur 
4-10 days after exposure. The lesion at the site of infection is, initially, a pustule that breaks down to form a 
painful, soft, ulcer with a necrotic base and irregular borders. Multiple lesions and inguinal adenopathy often 
develop. With lymph node involvement, fever, chills, and malaise may also develop. Other symptoms of 





The combination of a painful genital ulcer and tender suppurative inguinal adenopathy suggests the diagnosis of 
chancroid. A probable diagnosis of chancroid can be made if: 
 One or more painful genital ulcers (regional lymphadenopathy is also typical) 
 No evidence of T. pallidum infection by darkfield examination of ulcer exudate or by syphilis serologic 
testing performed at least 7 days after onset of ulcers 
 Test for herpes simplex virus performed on the ulcer exudate is negative 
A definitive diagnosis of chancroid requires the identification of H. ducreyi on special culture media. However, 
culture media for chancroid are not widely available. Nucleic acid amplification tests can be performed in clinical 
laboratories that have developed their own tests. 
Granuloma Inguinale/Donovanosis 
Clinical Presentation: 
Granuloma inguinale is a chronic, relapsing, granulomatous anogenital infection caused by the bacterium 
Klebsiella granulomatis (formerly known as Calymmatobacterium granulomatis), which is endemic in tropical 
and developing areas, including India, Guyana, New Guinea, central Australia, and southern Africa. Symptoms 
usually occur 1-12 weeks after infection. The infection begins with the appearance of relatively painless nodules 
that break down into shallow, sharply demarcated ulcers with a beefy-red friable base of granulation tissue. The 
lesions may occur on the skin, genitalia, or perineal areas, and slowly spread to the lower abdomen and thighs. 
The lesions may develop secondary bacterial infection and can co-exist with other sexually transmitted 
infections. 
Diagnostic Testing: 
Diagnosis requires visualization of Donovan bodies (numerous bacilli in the cytoplasm of macrophages 
demonstrated with Giemsa or Wright’s stain) in smears of scrapings from the ulcer base or histologic sections. 
Culture of C. granulomatis is difficult to perform and not routinely available. 
Lymphogranuloma Venereum 
Clinical Presentation: 
Lymphogranuloma venereum (LGV) is caused by three subtypes of C. trachomatis: serovars L1, L2, or L3. It is 
most often seen in tropical areas of Asia, Africa, South America, and the Caribbean. Symptoms appear 3-30 days 
after infection, and usually present as a painless ulcer or papule at the site of inoculation. Inguinal and femoral 
lymphadenopathy may also occur. Rectal exposure can result in mucoid or hemorrhagic rectal discharge, painful 
bowel movements, and constipation. Late manifestations include rectal and perirectal inflammation that can 





Diagnosis is based on clinical suspicion, epidemiologic information, and C. trachomatis testing. Genital and 
lymph node specimens (e.g., lesion swab, aspirate) may be tested for C. trachomatis by culture, direct 
immunofluorescence, or nucleic acid detection. To differentiate LGV from non-LGV C. trachomatis, special 
testing is generally necessary (e.g., genotyping) and may necessitate consultation with laboratory experts. 
Chlamydia serology (complement fixation titers >1:64 or microimmunofluorescence titers >1:256) can support 
the diagnosis in the appropriate clinical context. 
Genital Herpes 
Clinical Presentation: 
Genital herpes is a chronic, lifelong infection caused by herpes simplex virus (HSV) type 1 and type 2. Most cases 
of recurrent genital herpes are caused by HSV-2. Many persons with genital herpes have mild or unrecognized 
infections but intermittently shed the virus in the genital tract. When the ulcers do occur, they appear typically 
as one or more blisters on or around the genitals, rectum, or mouth. The blisters break, leaving tender ulcers 
that may take 2-4 weeks to heal the first time they occur. Other symptoms, such as fever, headache, muscle 
aches, malaise, and swollen lymph glands, may occur before appearance of the lesions. After the first episode of 
genital herpes, symptoms usually recur, but they tend to be milder and briefer. After the lesions erupt, they 
typically heal in 6-10 days. 
Neonatal herpes is a rare but serious condition occurring among infants exposed to HSV during birth. Although 
the disease may be limited to skin, eyes, or mucus membranes, disseminated disease involving the lungs, liver, 
adrenal glands, and central nervous system disease (encephalitis), may also occur and are associated with 
serious consequences. 
Diagnostic Testing: 
Isolation of HSV in cell culture or nucleic acid amplification tests such as polymerase chain reaction (PCR) are the 
preferred tests in persons with genital lesions; however, the sensitivity of the culture is low, especially for 
recurrent lesions. Viral culture isolates can be typed to determine if HSV-1 or HSV-2 is the cause of the infection.  
PCR for HSV DNA is considered more sensitive, and results are available sooner, than viral culture (3). 
Type-specific serologic tests may be useful: 
 in clinical diagnosis of genital herpes without laboratory confirmation; 
 for recurrent genital symptoms or atypical symptoms with negative HSV culture; 
 when a sex partner has known genital herpes. 
Genital Warts 
Clinical Presentation: 
Genital warts are the most recognized sign of genital human papillomavirus (HPV) infection. HPV types 6 and 11 
are usually associated with genital warts. Other HPV types that affect the anogenital region (i.e., types 16, 18, 
31, 33, and 35) are associated with cervical neoplasia. 
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Genital warts are usually flat, papular, or pedunculated growths on the genital mucosa, and often occur in 
clusters. They can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual 
contact with an infected person. 
Diagnostic Testing: 
Diagnosis of genital warts is made by visual inspection. Biopsy may confirm the diagnosis, but is generally 
needed only when the lesions do not respond to appropriate therapy or worsen during therapy. 
Trichomoniasis 
Clinical Presentation: 
Trichomoniasis, caused by the protozoan Trichomonas vaginalis, is the most common curable STD in sexually 
active women.  
Approximately 70% of people with trichomoniasis will have no symptoms. In women, a malodorous, yellow-
green vaginal discharge with vulvar irritation can occur. In men, trichomoniasis can cause urethral discharge or 
dysuria. 
Diagnostic Testing: 
Diagnosis of vaginal trichomoniasis is commonly performed by microscopy of vaginal secretions, although this 
method has a sensitivity of only approximately 60-70%, and requires evaluation of a wet preparation slide for 
optimal results. Other FDA-cleared tests for trichomoniasis in women include immunochromatographic capillary 
flow dipstick tests that can be performed at the point of care. Culture for T. vaginalis is also considered a 
sensitive and specific method of detection, and is commonly used when microscopy is negative. Among women, 
nucleic acid amplification testing is the most sensitive and specific test available for diagnosis.  
Counseling and HIV testing 
Healthcare providers should provide counseling to all persons with STDs, and recommend evaluation and 
treatment for their sex partners. Information should be provided about preventative measures and risk 
reduction interventions for STDs, including HIV, and should be tailored to each individuals’ risk behavior (4). 
Although HIV screening is recommended as a routine component of the newly arrived refugee medical screening 
examination, it is particularly important to offer HIV testing to refugees found to have other STDs. 
Further information on the prevention of STDs is available at the CDC Sexually Transmitted Diseases website and 
the 2015 STD Treatment Guidelines. 
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Table 1. Interpretation of Syphilis Serology Tests 
Nontreponemal test (e.g., RPR, 
VDRL) 
Treponemal (specific) test (e.g., 
FTA-ABS, TPPA) 
Likely interpretations and 
comments  
Nonreactive* Nonreactive No evidence of syphilis  
Reactive Reactive  Untreated syphilis OR 
 Previously treated late 
syphilis OR 
 Other spirochetal diseases 
Reactive Nonreactive False-positive result may be seen 
in certain acute or chronic 
infections (e.g., tuberculosis, 
hepatitis, malaria, early HIV 
infection), autoimmune diseases 
(e.g., systemic lupus, rheumatoid 
arthritis), injection drug use, 
pregnancy, and following 
vaccination (e.g., smallpox, MMR). 
Nonreactive Reactive  Very early untreated 
syphilis OR  
 Previously treated syphilis 
OR  
 Very late untreated 
syphilis  
Note: After successful 
treatment, a positive 
nontreponemal test 
usually becomes negative, 
whereas the treponemal 
test usually remains 
positive for life.  
*Note: Nontreponemal testing may have a false-negative result during primary syphilis in the very early stages 
or tertiary syphilis in the very late stages. Suggest presumptive treatment, and retesting if clinical suspicion is 
high. See CDC Sexually Transmitted Diseases Treatment Guidelines.  
Acronyms: Rapid plasma reagin (RPR); venereal disease research laboratory (VDRL) test; fluorescent treponemal 
antibody absorption (FTA-ABS); treponema pallidum particle agglutination (TPPA) assay.  
